文献速递泌尿生殖与妇科肿瘤放疗

极高危前列腺癌男性外照射放疗联合或不联合近距离放疗推量:一项大型多中心国际联盟分析

External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-09-28

这项来自4国16个中心的队列研究纳入极高危前列腺癌男性,比较剂量递增外照射放疗联合≥24个月雄激素剥夺治疗与联合近距离放疗推量且雄激素剥夺治疗≥12个月的结局。中位随访7.8年,两组前列腺癌特异性死亡和远处转移均无显著差异。作者认为需在接受强化系统治疗的男性中开展比较分析。

要点

  • 极高危前列腺癌中,外照射放疗联合近距离放疗推量相比单纯外照射放疗,前列腺癌特异性死亡和远处转移均无显著差异。
  • 中位随访7.8年,外照射放疗组前列腺癌特异性死亡6.7%、远处转移16.3%,外照射放疗联合近距离放疗推量组分别为5.9%和9.9%。
  • 作者认为需在接受强化系统治疗的男性中开展比较分析。

核心结论

  • 在极高危前列腺癌队列中,外照射放疗联合≥24个月雄激素剥夺治疗与联合近距离放疗推量且雄激素剥夺治疗≥12个月相比,临床意义结局无差异。
  • 作者认为需在接受强化系统治疗的男性中开展比较分析。

研究设计与样本

  • 这项队列研究来自4个国家的16个中心,纳入极高危前列腺癌男性,接受剂量递增外照射放疗联合≥24个月雄激素剥夺治疗或外照射放疗联合近距离放疗推量且雄激素剥夺治疗≥12个月。
  • 极高危按美国国家综合癌症网络标准定义(临床T3b-4、主要Gleason模式5或≥2项美国国家综合癌症网络高危特征),并在符合STAMPEDE试验入选标准的亚组中验证结果。
  • 采用逆概率治疗加权校正的Fine-Gray竞争风险回归比较两组的前列腺癌特异性死亡和远处转移。

主要发现

  • 整个队列中,270例接受外照射放疗,101例接受外照射放疗联合近距离放疗推量。
  • 中位随访7.8年,外照射放疗组和联合近距离放疗推量组分别有6.7%和5.9%死于前列腺癌,分别有16.3%和9.9%发生远处转移。
  • 外照射放疗联合近距离放疗推量对比外照射放疗,前列腺癌特异性死亡无显著差异(sHR 1.47,95%CI 0.57-3.75,P=0.42),远处转移无显著差异(sHR 0.72,95%CI 0.30-1.71,P=0.45)。
  • 在STAMPEDE定义的极高危亚组中结果相似:前列腺癌特异性死亡sHR 1.67(95%CI 0.48-5.81,P=0.42),远处转移sHR 0.56(95%CI 0.15-2.04,P=0.38)。

关键数值与推荐

  • 极高危定义采用美国国家综合癌症网络标准:临床T3b-4、主要Gleason模式5或≥2项美国国家综合癌症网络高危特征。
  • STAMPEDE试验入选标准亚组定义为满足以下至少2项:临床T3-4、Gleason 8-10或PSA≥40 ng/mL。
  • 外照射放疗组要求雄激素剥夺治疗≥24个月,外照射放疗联合近距离放疗推量组要求雄激素剥夺治疗≥12个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需在接受强化系统治疗的男性中开展比较分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Very-high-risk (VHR) prostate cancer (PC) is an aggressive subgroup with high risk of distant disease progression. Systemic treatment intensification with abiraterone or docetaxel reduces PC-specific mortality (PCSM) and distant metastasis (DM) in men receiving external beam radiation therapy (EBRT) with androgen deprivation therapy (ADT). Whether prostate-directed treatment intensification with the addition of brachytherapy (BT) boost to EBRT with ADT improves outcomes in this group is unclear. METHODS AND MATERIALS: This cohort study from 16 centers across 4 countries included men with VHR PC treated with either dose-escalated EBRT with ≥24 months of ADT or EBRT + BT boost with ≥12 months of ADT. VHR was defined by National Comprehensive Cancer Network (NCCN) criteria (clinical T3b-4, primary Gleason pattern 5, or ≥2 NCCN high-risk features), and results were corroborated in a subgroup of men who met Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trials inclusion criteria (≥2 of the following: clinical T3-4, Gleason 8-10, or PSA ≥40 ng/mL). PCSM and DM between EBRT and EBRT + BT were compared using inverse probability of treatment weight-adjusted Fine-Gray competing risk regression. RESULTS: Among the entire cohort, 270 underwent EBRT and 101 EBRT + BT. After a median follow-up of 7.8 years, 6.7% and 5.9% of men died of PC and 16.3% and 9.9% had DM after EBRT and EBRT + BT, respectively. There was no significant difference in PCSM (sHR, 1.47 [95% CI, 0.57-3.75]; P = .42) or DM (sHR, 0.72, [95% CI, 0.30-1.71]; P = .45) between EBRT + BT and EBRT. Results were similar within the STAMPEDE-defined VHR subgroup (PCSM: sHR, 1.67 [95% CI, 0.48-5.81]; P = .42; DM: sHR, 0.56 [95% CI, 0.15-2.04]; P = .38). CONCLUSIONS: In this VHR PC cohort, no difference in clinically meaningful outcomes was observed between EBRT alone with ≥24 months of ADT compared with EBRT + BT with ≥12 months of ADT. Comparative analyses in men treated with intensified systemic therapy are warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Patel SA, Ma TM, Wong JK, et al. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Int J Radiat Oncol Biol Phys. 2022. PMID: 36179990. doi:10.1016/j.ijrobp.2022.09.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。